We have calls in CVS Health (CVS), Walt Disney (DIS), Expedia (EXP) and Moderna (MRNA) expiring this week. I am recommending we roll them out two weeks. Note that the new calls expire on a Thursday, as the market is closed on Friday, April 7, in observance of Good Friday. With CVS and EXPE, we…
I am recommending we roll our Moderna (MRNA) call out two weeks and to a higher strike price to generate more income and capture more potential appreciation in the underlying shares. Current Stock Price: $141.21 Cost Basis: $186.60 Action: Buy to close the MRNA Mar Week Two (3/10) 140 Call for around $2.55 Sell to…
Our Moderna (MRNA) call is on track to expire worthless as the stock has continued to decline following earnings. The protective put we sold helped offset some of the initial post-earnings sell-off, but shares are down around 18% since we were assigned two weeks ago. I know this has been a frustrating position for many…
Moderna (MRNA) missed on earnings and the stock is sharply lower today. Let’s close our long put to reduce our cost basis on the position. Current Stock Price: $144.43 Cost Basis: $194.76 Action: Sell to close the MRNA Feb Week Four (2/24) 150 Put for around $5.65, but adjust as needed to close today New Cost…
I am recommending we sell a call against our Moderna (MRNA) shares to generate income. With the company scheduled to report earnings tomorrow, I want to use the cash we generate to help cover the cost of a protective put. Current Stock Price: $158.46 Cost Basis: $194.15 Action: Sell to open the MRNA Mar Week…
Moderna (MRNA) is currently trading 0.3% above the strike price of our MRNA Feb Monthly (2/17) 172.50 Put with the company scheduled to report earnings on Feb. 23. I am recommending we watch the put expire. If it expires worthless, we will wait until after the earnings announcement to reenter the position by selling a…
I am recommending we roll our Moderna (MRNA) put out two weeks to generate more income and reduce our net debit on the position. You can enter the second leg of today’s trade even if you were not in the previous one. Just be aware that we will be managing and tracking it based on…
Moderna (MRNA) rallied yesterday on news that its experimental RSV vaccine is nearly 84% effective against respiratory symptoms in older adults. Although it is giving back some of those gains today amid broader market weakness, our put remains well out of the money and is trading for just a few cents. I am recommending we…
Moderna (MRNA) has fallen more than 18% in the past two weeks since topping out above $212. This followed a sharp run-up in mid-December on news its personalized vaccine candidate reduces the risk of melanoma recurrence or death by 44% when given to patients in combination with Merck’s (MRK) Keytruda. Some of the selling can…
Moderna (MRNA) is holding onto the big gains it made after it was announced that its personalized vaccine candidate reduces the risk of melanoma recurrence or death by 44% when given to patients in combination with Merck’s (MRK) Keytruda. I am recommending we roll our put out two weeks to generate more income while lowering…
